Foundry Partners LLC Grows Stock Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Foundry Partners LLC grew its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 1,597.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 86,429 shares of the specialty pharmaceutical company’s stock after buying an additional 81,337 shares during the quarter. Foundry Partners LLC’s holdings in Jazz Pharmaceuticals were worth $10,730,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of JAZZ. Raymond James Financial Inc. acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth $11,373,000. HighTower Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 27.0% during the fourth quarter. HighTower Advisors LLC now owns 9,648 shares of the specialty pharmaceutical company’s stock worth $1,188,000 after purchasing an additional 2,054 shares in the last quarter. Avantax Advisory Services Inc. acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth $264,000. Envestnet Portfolio Solutions Inc. lifted its position in shares of Jazz Pharmaceuticals by 19.0% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 3,146 shares of the specialty pharmaceutical company’s stock worth $387,000 after purchasing an additional 502 shares in the last quarter. Finally, Corient Private Wealth LLC lifted its position in shares of Jazz Pharmaceuticals by 34.5% during the fourth quarter. Corient Private Wealth LLC now owns 10,857 shares of the specialty pharmaceutical company’s stock worth $1,335,000 after purchasing an additional 2,784 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $116.35, for a total value of $116,350.00. Following the completion of the transaction, the chief executive officer directly owned 439,307 shares of the company’s stock, valued at approximately $51,113,369.45. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Seamus Mulligan bought 100,000 shares of the company’s stock in a transaction on Friday, May 9th. The stock was bought at an average cost of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the purchase, the director owned 100,000 shares of the company’s stock, valued at approximately $9,826,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 2,500 shares of company stock worth $277,930. 4.30% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Trading Down 1.7%

Shares of Jazz Pharmaceuticals stock opened at $112.87 on Friday. The company’s fifty day simple moving average is $109.13 and its 200-day simple moving average is $118.28. The company has a market cap of $6.83 billion, a price-to-earnings ratio of 15.05, a PEG ratio of 5.74 and a beta of 0.32. The company has a current ratio of 3.38, a quick ratio of 2.97 and a debt-to-equity ratio of 1.28. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The business had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. During the same quarter in the prior year, the firm earned $2.68 EPS. The firm’s quarterly revenue was down .5% on a year-over-year basis. As a group, sell-side analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Royal Bank Of Canada cut their price target on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. Robert W. Baird lowered their price target on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. Wall Street Zen lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 15th. Morgan Stanley lowered their price target on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday, May 7th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday. They set a “buy” rating and a $152.00 price target for the company. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $181.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.